摘要
[目的]研究乳腺癌新辅助化疗后行前哨淋巴结活检(SLNB)的准确性、可行性。[方法]比较接受新辅助化疗的乳腺癌和未接受新辅助化疗乳腺癌SLNB的成功率、灵敏度、假阴性率、准确性,以及SLNB、腋窝淋巴结清扫(ALND)淋巴结检出枚数,同时对影响SLNB的因素进行讨论。[结果]26例新辅助化疗后乳腺癌SLNB的成功率、灵敏度、假阴性率、准确性分别为92.3%、90.9%、9.1%和95.8%,SLNB和ALND平均检出淋巴结分别为1.5、13.5枚,对比非新辅助化疗病例,均无明显统计学差异。肿瘤的位置、多灶性、前哨淋巴结的数量等可能是影响乳腺癌新辅助化疗后SLNB的因素。[结论]乳腺癌新辅助化疗后SLNB基本上是安全可行的。
[Purpose] To investigate the feasibility and accuracy of sentinel lymph node biopsy （SLNB） after neoadjuvant chemotherapy for patients with breast cancer. [Methods] The differences of identified rate, sensitivity ,false-negative rate, accuracy of SLNB, and the number of lymph nodes of SLNB and axillary lymph nodes dissection（ALND） between neoadjuvant group and non-neoadju- vant group were compared,and influencing factors for SLNB were discussed. [Results] A total of 26 patients with neoadjuvant chemotherapy followed by SLNB were enrolled. The SLN identified rate, sensitivity, false-negative rate and accuracy were 92.3%, 90.9%, 9.1% and 95.8%, respective- ly. The number of lymph nodes of SLNB and ALND was 1.5 and 13.5 ,respectively.There was no significant difference in these indicators between neoadjuvant group and non-neoadjuvant group. Location of the tumor, multicentric disease and number of SLN might be important factors affecting SLNB after neoadjuvant chemotherapy for breast cancer. [Conclusions] SLNB is feasible and ap- plicable for patients with operable breast disease who have received neoadjuvant chemotherapy.
出处
《肿瘤学杂志》
CAS
2012年第12期935-938,共4页
Journal of Chinese Oncology
基金
浙江省卫生厅医药卫生科技项目(2009B031)
关键词
乳腺肿瘤
前哨淋巴结活检
新辅助化疗
腋窝淋巴结清扫
breast neoplasms
sentinel lymph node biopsy （SLNB）
neoadjuvant chemotherapy
axillary lymph nodes disseetion（ALND）
